Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2022

Jun 9, 2022

30718_dirs_2022-06-09_e870f2fa-7c14-4e99-9390-e3a5553ec574.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2022-06-07

Reporting Person: HIGGINS JOHN L (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-06-07 Common Stock M 1000 $66.90 Acquired 5606 Direct
2022-06-07 Common Stock S 1000 $364.31 Disposed 4606 Direct
2022-06-08 Common Stock M 600 $66.90 Acquired 5206 Direct
2022-06-08 Common Stock S 600 $366.09 Disposed 4606 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-06-07 Stock Options (Right to Buy) $66.90 M 1000 Disposed 2022-10-24 Common Stock (5000) Direct
2022-06-08 Stock Options (Right to Buy) $66.90 M 600 Disposed 2022-10-24 Common Stock (4000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Options (Right to Buy) $87.39 2023-10-30 Common Stock (4000) 4000 Direct
Stock Options (Right to Buy) $91.78 2024-10-30 Common Stock (4000) 4000 Direct
Stock Options (Right to Buy) $87.34 2025-10-28 Common Stock (4260) 4260 Direct
Stock Options (Right to Buy) $101.19 2026-10-26 Common Stock (3985) 3985 Direct
Stock Options (Right to Buy) $125.05 2027-10-27 Common Stock (3125) 3125 Direct
Stock Options (Right to Buy) $179.84 2028-10-25 Common Stock (1898) 1898 Direct
Stock Options (Right to Buy) $201.64 2029-10-24 Common Stock (2011) 2011 Direct
Stock Options (Right to Buy) $255.69 2030-10-29 Common Stock (1507) 1507 Direct
Stock Options (Right to Buy) $515.24 2031-10-28 Common Stock (633) 633 Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 364.0000 to 364.6400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 366.0000 to 366.1900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The option vests on the earlier of the one year anniversary of the grant date (10/28/21) or the date of Bio-Techne's 2022 annual meeting of shareholders.